ArticleJournal of nanobiotechnology2026
AIEgen-mediated integration of plain DNA and hydrophobic compounds enabling three-in-one nanosystems for carrier-free delivery.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
DNA has been serving as a powerful and programmable vector for drug delivery, yet facile strategies for the direct loading of hydrophobic payloads onto DNA vehicles are still lacking but highly demanded. In this work, we report an AIEgen-mediated approach for the integration of plain DNA and hydrophobic molecules into nanospheres upon heating treatment. The broad applicability of this strategy is established by loading nine different hydrophobic molecules with high loading capacity, including six therapeutic drugs and three fluorescent dyes. Owing to the compact configuration, the nano-systems show superior stability under physiologically relevant conditions while the AIEgen displays significantly enhanced fluorescent signal and reactive oxygen species-generating ability upon light irradiation. In vitro studies validate the successful cellular delivery of the nanosystems, as evidenced by effective cell staining with fluorescent dyes and synergistic cytotoxicity from the combined action of loaded drugs and AIEgen-mediated photodynamic therapy (PDT). Finally, by using sorafenib and an antisense oligonucleotide (ASO), we demonstrate the synergistic antitumor efficacy of the nanodrug in vitro and in vivo: while ASO prolongs intracellular drug retention by down-regulating the efflux factor P-glycoprotein, sorafenib can amplify the PDT efficacy of the AIEgen by depleting glutathione and glutathione peroxidase 4. Therefore, our work establishes an effective AIEgen-mediated and heat-promoted strategy for creating multifunctional nanosystems, which may find widespread application in carrier-free delivery for disease theranostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.